Last checked at 1 Aug 2016 07:00
1 August 2016 |
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Notice of Interim Results
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), a leading developer and manufacturer of advanced products for the global surgical and wound care markets, will announce its interim results for the six months ended 30 June 2016 on Wednesday 14 September 2016.
A briefing for analysts will be held at 09.00am on the day of the results. Please contact Consilium Strategic Communications for further details.
- End -
For further information, please visit our new website www.admedsol.com or contact:
Advanced Medical Solutions Group plc | Tel: +44 (0) 1606 545508 |
Chris Meredith, Chief Executive Officer Mary Tavener, Group Finance Director | |
Consilium Strategic Communications | Tel: +44 (0) 20 3709 5700 |
Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Hendrik Thys | AMS@consilium-comms.com |
Investec Bank PLC (NOMAD & Broker) | Tel: +44 (0) 20 7597 5970 |
Gary Clarence / Daniel Adams / Patrick Robb |
About Advanced Medical Solutions Group plc - see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.
AMS's products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 70 countries via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Company has 510 employees. For more information please see www.admedsol.com.